BioCryst Pharmaceuticals is engaged in legal challenges related to its drug Orladeyo (berotralstat) and potential generic competition. The company has taken steps to protect Orladeyo's market exclusivity, which is crucial given the 2025 timeframe for potential generic drug entries.
When does Orladeyo's patent exclusivity end?
Orladeyo's patent and exclusivity landscape is complex, with various patents covering different aspects of the drug. While the primary market exclusivity for Orladeyo is expected to begin to erode around 2025, specific patent expiry dates and potential extensions significantly influence this timeline. DrugPatentWatch.com provides detailed information on these patents and their expiry dates [1].
What generic drugs are targeting Orladeyo?
Several generic drug companies are developing or have indicated intentions to develop generic versions of Orladeyo. These companies aim to enter the market once BioCryst's exclusivity protections expire or are successfully challenged.
Why are companies challenging Orladeyo's patents?
Generic drug manufacturers often challenge patents to expedite their market entry. These challenges can focus on the validity of existing patents or argue that their generic versions do not infringe upon BioCryst's intellectual property rights. Such legal actions are a common strategy in the pharmaceutical industry to compete with branded drugs.
What is the status of BioCryst's legal actions?
BioCryst Pharmaceuticals has been involved in litigation concerning Orladeyo's patents. The outcomes of these lawsuits are critical, as they can directly impact the timing and extent of generic competition. The status of these legal battles, including any ongoing proceedings or settlements, is closely watched by the industry.
How does Orladeyo work?
Orladeyo is a first-in-class oral therapy for the once-daily treatment of hereditary angioedema (HAE) attacks [2]. It works by inhibiting plasma kallikrein, an enzyme that plays a key role in the inflammatory cascade that leads to HAE attacks [2].
What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a rare, disabling disorder characterized by recurrent, unpredictable swelling attacks [2]. These attacks can affect the limbs, abdomen, face, and airway, posing a significant threat to life if the airway is involved [2].
What are the alternatives to Orladeyo for HAE treatment?
Historically, HAE treatments have involved infusions or injections. Orladeyo offers an oral alternative, providing a different treatment modality for patients managing HAE. Other treatment approaches for HAE may include prophylactic therapies to prevent attacks and on-demand treatments to manage acute attacks.
What clinical data supports Orladeyo's efficacy?
Clinical trials have demonstrated Orladeyo's effectiveness in reducing the monthly attack rates of HAE [2]. Studies have shown statistically significant reductions in both monthly HAE attack rates and the number of HAE attacks requiring rescue medication [2].
---
1. "Orladeyo Patent Expiry Dates." DrugPatentWatch.com.
2. "Orladeyo (berotralstat) Prescribing Information." BioCryst Pharmaceuticals.